234 related articles for article (PubMed ID: 15968483)
1. [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].
Schlander M
Med Klin (Munich); 2005 Jun; 100(6):314-24. PubMed ID: 15968483
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
[TBL] [Abstract][Full Text] [Related]
3. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
Schwermann T; Greiner W; v d Schulenburg JM
Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
[TBL] [Abstract][Full Text] [Related]
4. Cost containment: Europe. Germany.
Burchardi H; Schuster HP; Zielmann S
New Horiz; 1994 Aug; 2(3):364-74. PubMed ID: 8087598
[TBL] [Abstract][Full Text] [Related]
5. Strategic choices for cost containment under a reformed U.S. health care system.
Kilbreth E; Cohen AB
Inquiry; 1993; 30(4):372-88. PubMed ID: 8288401
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
Seay M; Varma P
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
[TBL] [Abstract][Full Text] [Related]
7. [Political decisions and implementation: efficient management of a psychiatric department be successful despite working time law, practice fee and other innovations?].
Wittmund B
Psychiatr Prax; 2005 Apr; 32(3):153-4. PubMed ID: 15818523
[No Abstract] [Full Text] [Related]
8. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
Mueller EA; Kirch W
Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
11. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
12. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
13. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
Grund J; Husbyn H
Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
[TBL] [Abstract][Full Text] [Related]
14. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
[TBL] [Abstract][Full Text] [Related]
15. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
16. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
Yang BM; Bae EY; Kim J
Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
[TBL] [Abstract][Full Text] [Related]
18. Expenditures for prescription drugs: too much or not enough?
Schumock GT; Walton SM
Healthc Financ Manage; 2003 Oct; 57(10):34-8, 41. PubMed ID: 14560578
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
20. Missouri Medicaid reform...what can physicians do?
Halverson LW
Mo Med; 2006; 103(2):102-5. PubMed ID: 16703704
[No Abstract] [Full Text] [Related]
[Next] [New Search]
